Floatz logo

Inno-206

t(11;14)(q13;q32)

M.D. Anderson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the t(11;14)(q13;q32) cohort.

Asset / SponsorPhaseRating
Acalabrutinib
M.D. Anderson Cancer Center
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2CCC
PREDNISONE TABLETS
M.D. Anderson Cancer Center
Phase 2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2CCC
Venetoclax
M.D. Anderson Cancer Center
Phase 2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →